Rasagilinum
 |
Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt. |
| Cognitores | |
|---|---|
| ChemSpider | 2314553 |
| PubChem | 3052776 |
| DrugBank | DB01367 |
| Natura chemica | |
| |
| |
| Formula chemica | C 12H 13N |
| Massa molaris | 171.238 g/mol |
| Natura pharmacologica | |
| Codex ATC | N04BD02 (WHO) |
| Semivita biologica | 3 h |
| Metabolismus | iecore (hepaticus): CYP1A2 |
| Excretio | renibus, faecibus |
| Ad usum therapeuticum | |
| Applicatio | per os |
| MedlinePlus | a606017 (Anglice) |
Rasagilinum est medicamentum pharmaceuticum et inhibitor monoaminorum oxidasis B irreversibilis[1]. Substantia in morbo Parkinson tractando et maturo[2] et in cursibus progressivis.
Natura Rasagilini
[recensere | fontem recensere]Natura chemica
[recensere | fontem recensere]Nomen suum est (R)-N-prop-2-inyl-2,3-dihydro-1H-inden-1-aminum. Massa molaris sua 171.238 g/mol.
Natura pharmacologica
[recensere | fontem recensere]Rasagilinum est MAO-B inhibitor irreversibilis et medicamentum therapia morbi Parkinson et maturi et progressivi. Codex ATC est N04BD02 (WHO). Inhibitio monoaminorum oxidasis B potentissima est, etenim quinquies, decies quam Selegilino.
Effectus Rasagilini
[recensere | fontem recensere]Interactiones
[recensere | fontem recensere]Consumptio simul Rasagilini et cuiusvis inhibitoris reabsorptionis serotonini (per exemplum: sertralinum) periculo syndromae serotonini causa saepe non commendatur[3][4], quamquam investigatio Canadiensis syndroma serotoni raro esse dixit, donec doses inhibitoris reabsorptionis serotonini parve deligantur[5].
Notae
[recensere | fontem recensere]- ↑ Oldfield V., Keating G. M., Perry C. M. (2007). "Rasagiline: a review of its use in the management of Parkinson's disease". Drugs 67 (12): 1725-47
- ↑ Hattori N., Takeda A., Takeda S., Nishimura A., Kitagawa T., Mochizuki H., Nagai M., Takahashi R. (2018). "Rasagiline monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan". Parkinsonism Relat Disord: doi: 10.1016/j.parkreldis.2018.08.024
- ↑ Hébant B., Guillaume M., Desbordes M., Gaillon G., Maltête D., Lefaucheur R. (2016). "Combination of paroxetine and rasagiline induces serotonin syndrome in a parkinsonian patient". Rev Neurol (Paris) 172 (12): 788-9
- ↑ Duval F., Flabeau O., Razafimahefa J., Spampinato U., Tison F. (2013). "Encephalophaty associated with rasagiline and sertraline in Parkinson's disease: possible serotonin syndrome". Mov Disord 28 (10): 1464
- ↑ Aboukarr A., Giudice M. (2018). "Interaction between Monoamine Oxidase B Inhibitors and Selective Serotonin Reuptake Inhibitors". Can J Hosp Pharm 71 (3): 196-207
Nexus interni
Nexus externi
[recensere | fontem recensere]- Fabrizio Stocchi: Eritne somnus therapiae ad morbum tardandum verum? (oratio), (Italice)